Strong growth in the domestic market is another positive factor, as retail sales are estimated to have risen by around 17% in 2009. Indications so far are that growth will be high in 2010 too. Large Indian players who were focused on the US and European generic markets have turned their attention back to the domestic market.

Multinational pharmaceutical companies are chasing the same domestic market. They are launching new products, beefing up their marketing infrastructure and also adopting new strategies such as tapping rural markets. These strategies are getting them more market visibility but the impact on their financial performance has been more gradual.

Graphic: Yogesh Kumar/Mint

Sun Pharmaceutical Industries Ltd will benefit from revenue from the launch of generic Eloxatin in the US market. Lupin Ltd and Cipla Ltd are expected to see margins improve due to a better product mix. Among the smaller companies, Glenmark Pharmaceuticals Ltd and Biocon Ltd are expected to report good results.

While the March quarter for pharmaceutical companies will be a good one, investors will be keen on hearing management commentary about the outlook for the year ahead. That should set the tone for stock valuations.

Write to us at